1. Histone deacetylase inhibitors
    Paul A. Marks, 2013, Molecular Oncology CrossRef
  2. HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia
    Marco Spreafico et al, 2020, Frontiers in Cell and Developmental Biology CrossRef
  3. Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
    Peijun Cao et al, 2022, Frontiers in Chemistry CrossRef
  4. HDAC8 as a target in drug discovery: Function, structure and design
    Qianlong Zhao et al, 2024, European Journal of Medicinal Chemistry CrossRef
  5. Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
    Vera Miranda-Gonçalves et al, 2018, Frontiers in Genetics CrossRef
  6. Expression of HDAC8 indicates poor prognosis of esophageal squamous cell carcinoma and progression to advanced stage
    Cheng Yufeng et al, 2019, International Journal of Cancer and Oncology CrossRef
  7. Synthesis of N‐aminophalimides derived from α‐amino acids: Theoretical study to find them as HDAC8 inhibitors by docking simulations and in vitro assays
    José Eduardo Guzmán Ramírez et al, 2023, Chemical Biology & Drug Design CrossRef
  8. The Relationship between Histone Deacetylase (HDACs) and Gastric Cancer
    珊 徐, 2020, Advances in Clinical Medicine CrossRef
  9. Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis
    Tino Heimburg et al, 2016, Journal of Medicinal Chemistry CrossRef
  10. A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds
    Hua Zhang et al, 2024, Current Medicinal Chemistry CrossRef
  11. Comprehensive Analysis of the Differential Expression and Prognostic Value of Histone Deacetylases in Glioma
    Jinwei Li et al, 2022, Frontiers in Cell and Developmental Biology CrossRef
  12. In silico identification of dual HDAC8 and MMP9 inhibitors by pharmacophore modeling, molecular docking, and molecular dynamics simulation studies for development of antitumour agent
    Kakali Sarkar et al, 2024, Interactions CrossRef
  13. Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives
    Gebremedhin S. Hailu et al, 2017, Journal of Medicinal Chemistry CrossRef
  14. Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
    David S. Schrump, 2009, Clinical Cancer Research CrossRef
  15. Progress in the research of epigenetic regulators in cancer therapy
    LongJiang DI et al, 2023, SCIENTIA SINICA Vitae CrossRef
  16. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
    Dimitrios Schizas et al, 2018, World Journal of Gastroenterology CrossRef
  17. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro
    Sonia Abou Najem et al, 2019, Current Molecular Pharmacology CrossRef
  18. Epigenetic control of gene function in schistosomes: a source of therapeutic targets?
    Alejandro Cabezas-Cruz et al, 2014, Frontiers in Genetics CrossRef
  19. New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma
    Sarah Meneceur et al, 2024, Journal of Cellular and Molecular Medicine CrossRef
  20. Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus
    Natália Lourenço de Freitas et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
  21. High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors
    Wenxiu Zhao et al, 2022, Frontiers in Oncology CrossRef
  22. Characterization of the HDAC1 Complex That Regulates the Sensitivity of Cancer Cells to Oxidative Stress
    Takuya Kato et al, 2009, Cancer Research CrossRef
  23. B7-H3-targeted Radioimmunotherapy of Human Cancer
    Benjamin B. Kasten et al, 2020, Current Medicinal Chemistry CrossRef
  24. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
    Jianwei Feng et al, 2022, Frontiers in Pharmacology CrossRef
  25. Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity
    Jinbo Huang et al, 2023, Journal of Medicinal Chemistry CrossRef
  26. Acetylation in Tumor Immune Evasion Regulation
    Jun Lu et al, 2021, Frontiers in Pharmacology CrossRef
  27. Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
    Jorseth Rodelo Gutiérrez et al, 2022, Current Medicinal Chemistry CrossRef
  28. Down expression of lnc-BMP1-1 decreases that of Caveolin-1 is associated with the lung cancer susceptibility and cigarette smoking history
    Xiaoxuan Ling et al, 2020, Aging CrossRef
  29. Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases
    Fatma H. Al-Awadhi et al, 2020, ACS Chemical Neuroscience CrossRef
  30. Expression of acetylated histones H3 and H4 and histone deacetylase enzymes HDAC1, HDAC2 and HDAC6 in simple mammary carcinomas of female dogs
    Igor Luiz Salardani Senhorello et al, 2023, Frontiers in Genetics CrossRef
  31. Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma
    Louis Williams et al, 2019, Oncology & Hematology Review (US) CrossRef
  32. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
    Christian A. Hassig et al, 2008, Molecular Cancer Therapeutics CrossRef
  33. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
    Faria Sultana et al, 2020, Current Medicinal Chemistry CrossRef
  34. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
    Tingting Liu et al, 2020, Journal of Medicinal Chemistry CrossRef